Tysabri and Progressive Multifocal Leukoencephalopathy: Legal Options and California Statute of Limitations
From General Health Awareness to Specific Legal Concerns
For decades, general health and science communication has served as the foundation for public understanding of medical treatments and their associated risks. This legacy context emphasizes the importance of informed decision-making when patients and healthcare providers evaluate therapeutic options. Within this framework, the focus has traditionally been on broad safety profiles and population-level outcomes, allowing individuals to weigh benefits against potential adverse effects in a balanced manner. As we pivot from this general health perspective to a more specific occupational exposure concern, the discussion narrows to the real-world implications of pharmaceutical risk management. In the case of Tysabri, a medication used for certain chronic conditions, the recognized risk of progressive multifocal leukoencephalopathy (PML) has prompted significant attention from both medical and legal communities. For individuals who have been exposed to Tysabri and subsequently developed PML, the question of legal recourse becomes paramount. This is particularly relevant in California, where statutes of limitations impose strict deadlines for filing claims. The transition from general health awareness to occupational exposure involves recognizing that patients and their families must navigate not only medical complexities but also legal timelines. Understanding these constraints is essential for those seeking accountability, as the window for action is finite and requires prompt attention to preserve legal rights.
Tysabri and PML: Medical Evidence and Risk Factors
Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in patients who are immunocompromised, and three risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered in the context of expected benefit when initiating and continuing treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML is variable and can include progressive neurological deficits such as weakness, gait disturbance, cognitive impairment, visual changes, and speech difficulties. Diagnosis is typically confirmed by brain MRI showing characteristic white matter lesions and detection of JCV DNA in cerebrospinal fluid via polymerase chain reaction (PCR). Because PML can be rapidly progressive, healthcare professionals are instructed to monitor patients on Tysabri for any new sign or symptom suggestive of PML and to withhold dosing immediately at the first such sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these monitoring recommendations, the boxed warning acknowledges that PML usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Mechanism of PML and Additional Risks
The mechanistic pathway linking Tysabri to PML involves its action as an alpha-4 integrin antagonist. Tysabri binds to alpha-4 integrins on the surface of lymphocytes, blocking their adhesion to endothelial cells and thereby preventing their migration across the blood-brain barrier into the central nervous system. This reduces inflammatory activity in multiple sclerosis but also impairs immune surveillance against JCV in the brain. Under normal conditions, JCV is controlled by the immune system; however, with reduced T-cell trafficking into the CNS, JCV can reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the clinical syndrome of PML. The risk is highest in patients with anti-JCV antibodies, as these antibodies indicate prior exposure to the virus and potential for reactivation. In addition to PML, Tysabri increases the risk of other serious infections, including herpes encephalitis and meningitis caused by herpes simplex and varicella zoster viruses. Serious, life-threatening, and sometimes fatal cases have been reported in the postmarketing setting, with onset ranging from a few months to several years of treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The FDA Adverse Event Reporting System (FAERS) data show that the most frequently reported adverse events associated with Tysabri include fatigue, multiple sclerosis relapse, headache, gait disturbance, fall, memory impairment, asthenia, and balance disorder (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these reports do not directly confirm PML, they reflect the neurological and functional impairments that may overlap with early PML symptoms.
Legal Considerations and California Statute of Limitations
For patients who have developed PML after Tysabri exposure, legal considerations may arise regarding the adequacy of warnings provided by the manufacturer. The boxed warning clearly states the increased risk of PML and identifies risk factors, but questions may be raised about whether patients and healthcare providers were sufficiently informed about the magnitude of risk, the need for regular monitoring, and the limitations of risk mitigation strategies. The TOUCH Prescribing Program is a restricted distribution program that requires patients to be enrolled, read a Medication Guide, understand the risks, and sign a Patient Enrollment Form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Pharmacies and infusion centers must be specially certified to dispense or infuse Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, PML continues to occur, and affected patients may seek legal counsel to explore whether the warnings were adequate or whether the manufacturer failed to take appropriate steps to prevent harm. In California, the statute of limitations for personal injury claims related to Tysabri and PML is generally two years from the date of injury or from the date the injury was discovered, or reasonably should have been discovered. For wrongful death claims, the statute is typically two years from the date of death. Given the latency between Tysabri exposure and PML onset—which can be months to years—the timeline for filing a claim may be complex. Patients who develop PML after more than two years of treatment may have difficulty pinpointing when the injury occurred, and the discovery rule may apply, allowing the statute to begin running when the patient knew or should have known that Tysabri caused the PML. It is important for affected individuals to consult with an attorney promptly to preserve their legal rights.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the statute of limitations for Tysabri PML claims in California?
In California, the statute of limitations for personal injury claims related to Tysabri and PML is generally two years from the date of injury or from the date the injury was discovered, or reasonably should have been discovered. For wrongful death claims, the statute is typically two years from the date of death. The discovery rule may apply, so it is crucial to consult an attorney promptly.
What are the risk factors for developing PML while on Tysabri?
Three risk factors have been identified: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing treatment.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Related Articles
References
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.